450 related articles for article (PubMed ID: 28426108)
1. MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial.
Patel UB; Brown G; Machado I; Santos-Cores J; Pericay C; Ballesteros E; Salud A; Isabel-Gil M; Montagut C; Maurel J; Ramón-Ayuso J; Martin N; Estevan R; Fernandez-Martos C
Ann Oncol; 2017 Feb; 28(2):344-353. PubMed ID: 28426108
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
3. MRI of Extramural Venous Invasion in Locally Advanced Rectal Cancer: Relationship to Tumor Recurrence and Overall Survival.
Zhang XY; Wang S; Li XT; Wang YP; Shi YJ; Wang L; Wu AW; Sun YS
Radiology; 2018 Dec; 289(3):677-685. PubMed ID: 30152742
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy may improve disease-free survival in patients with rectal cancer positive for MRI-detected extramural venous invasion following chemoradiation.
Chand M; Rasheed S; Heald R; Swift I; West N; Rao S; Tekkis P; Brown G
Colorectal Dis; 2017 Jun; 19(6):537-543. PubMed ID: 27673438
[TBL] [Abstract][Full Text] [Related]
5. Early MRI predictors of disease-free survival in locally advanced rectal cancer from the GRECCAR 4 trial.
Nougaret S; Castan F; de Forges H; Vargas HA; Gallix B; Gourgou S; Rouanet P;
Br J Surg; 2019 Oct; 106(11):1530-1541. PubMed ID: 31436325
[TBL] [Abstract][Full Text] [Related]
6. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Bosset JF; Calais G; Mineur L; Maingon P; Stojanovic-Rundic S; Bensadoun RJ; Bardet E; Beny A; Ollier JC; Bolla M; Marchal D; Van Laethem JL; Klein V; Giralt J; Clavère P; Glanzmann C; Cellier P; Collette L;
Lancet Oncol; 2014 Feb; 15(2):184-90. PubMed ID: 24440473
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant CAPOX and bevacizumab alone for locally advanced rectal cancer: long-term results from the N-SOG 03 trial.
Tomida A; Uehara K; Hiramatsu K; Maeda A; Sakamoto E; Okada Y; Kurumiya Y; Nakayama G; Nakamura M; Aiba T; Nagino M;
Int J Clin Oncol; 2019 Apr; 24(4):403-410. PubMed ID: 30471067
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer.
van Dijk TH; Tamas K; Beukema JC; Beets GL; Gelderblom AJ; de Jong KP; Nagtegaal ID; Rutten HJ; van de Velde CJ; Wiggers T; Hospers GA; Havenga K
Ann Oncol; 2013 Jul; 24(7):1762-1769. PubMed ID: 23524865
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine and Oxaliplatin Prior and Concurrent to Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer: Long-Term Outcome.
Hess V; Winterhalder R; von Moos R; Widmer L; Stocker P; Jermann M; Herrmann R; Koeberle D
Clin Colorectal Cancer; 2017 Sep; 16(3):240-245. PubMed ID: 27687815
[TBL] [Abstract][Full Text] [Related]
10. MRI predictive factors for tumor response in rectal cancer following neoadjuvant chemoradiation therapy--implications for induction chemotherapy?
Yu SK; Tait D; Chau I; Brown G
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):505-11. PubMed ID: 24074924
[TBL] [Abstract][Full Text] [Related]
11. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
[TBL] [Abstract][Full Text] [Related]
12. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes.
Gollins S; Sun Myint A; Haylock B; Wise M; Saunders M; Neupane R; Essapen S; Samuel L; Dougal M; Lloyd A; Morris J; Topham C; Susnerwala S
J Clin Oncol; 2011 Mar; 29(8):1042-9. PubMed ID: 21263095
[TBL] [Abstract][Full Text] [Related]
13. MRI-based EMVI positivity predicts systemic recurrence in rectal cancer patients with a good tumor response to chemoradiotherapy followed by surgery.
Cho MS; Park YY; Yoon J; Yang SY; Baik SH; Lee KY; Kim IY; Kim NK
J Surg Oncol; 2018 Jun; 117(8):1823-1832. PubMed ID: 29790177
[TBL] [Abstract][Full Text] [Related]
14. Survival outcomes of different neoadjuvant treatment regimens in patients with locally advanced rectal cancer and MRI-detected extramural venous invasion.
Chen M; Ma Y; Song YW; Huang J; Gao YH; Zheng J; He F
Cancer Med; 2023 Nov; 12(21):20523-20537. PubMed ID: 37864414
[TBL] [Abstract][Full Text] [Related]
15. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience.
Patel UB; Taylor F; Blomqvist L; George C; Evans H; Tekkis P; Quirke P; Sebag-Montefiore D; Moran B; Heald R; Guthrie A; Bees N; Swift I; Pennert K; Brown G
J Clin Oncol; 2011 Oct; 29(28):3753-60. PubMed ID: 21876084
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
Chua YJ; Barbachano Y; Cunningham D; Oates JR; Brown G; Wotherspoon A; Tait D; Massey A; Tebbutt NC; Chau I
Lancet Oncol; 2010 Mar; 11(3):241-8. PubMed ID: 20106720
[TBL] [Abstract][Full Text] [Related]
17. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
18. Prognostic value of MRI in assessing extramural venous invasion in rectal cancer: multi-readers' diagnostic performance.
Bae JS; Kim SH; Hur BY; Chang W; Park J; Park HE; Kim JH; Kang HJ; Yu MH; Han JK
Eur Radiol; 2019 Aug; 29(8):4379-4388. PubMed ID: 30617483
[TBL] [Abstract][Full Text] [Related]
19. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
